Drugs / Gallium-68 NODAGA-JR11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04897542 | Dec 2020 → Dec 2023 | neuroendocrine neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium-68 NODAGA-JR11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04897542 ↗ |
| Modality | Diagnostic / imaging agent | “for the diagnostic imaging of metastatic, well-differentiated Neuroendocrine Tumors using PET/CT” NCT04897542 ↗ |
| Route | Intravenous | “single intravenous injection” NCT04897542 ↗ |